---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-009859"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:30:05.841128+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GeoVax FY2024 net loss $25.0M; BARDA award yields $4.0M revenue; key trials advancing

## Summary
- Net loss $25.0M vs $26.0M in 2023; revenue of $4.0M from BARDA Project NextGen contract (no revenue in 2023).
- Cash $5.5M at Dec 31, 2024, down from $6.5M; R&D expense $23.7M (up from $20.7M) on trial manufacturing.
- BARDA $400M award supports 10,000-patient Phase 2b trial of GEO-CM04S1; manufacturing and sites confirmed.
- DSMB cleared experimental arm of Phase 2 CLL trial after mRNA control arm failed primary endpoint.
- Phase 2 booster data for GEO-CM04S1 in healthy adults expected H1 2025; GEO-MVA clinical eval expected H2 2025.

## SEC filing metadata
- accession: 0001437749-25-009859
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774925009859/0001437749-25-009859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774925009859/govx20250327_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-009859
- JSON: https://secwatch.observer/filing/0001437749-25-009859.json
- Plain text: https://secwatch.observer/filing/0001437749-25-009859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.